Evidence map›Paper›PMID 42057916›Full record

ReviewCurrent research in toxicology2026

A mechanistic evaluation of the metabolism disrupting potential of methyl

A N Buerger, M J Vincent, S Fitch, B Rivera, N Engel, J Zhang, E K Rushton, S J Borghoff

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current research in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A N BuergerToxStrategies LLC, Cincinnati, OH, United States.
M J VincentToxStrategies LLC, Cincinnati, OH, United States.
S FitchToxStrategies LLC, Houston, TX, United States.
B RiveraToxStrategies LLC, Asheville, NC, United States.
N EngelEvonik Oxeno GmbH & Co. KG, Marl, Germany.
J ZhangSABIC China Holding Company, Beijing, China.
E K RushtonLyondellBasell Industries Holdings, Rotterdam, Netherlands.
S J BorghoffToxStrategies LLC, Durham, NC, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

European authoritative and regulatory assessments of endocrine disruption increasingly incorporate evaluation of metabolism disrupting potential, yet there are no regulatory- or authority-validated models or guidance to identify metabolism disrupting agents (MDAs), which are agents that increase the risk of developing metabolic disorders. Methyl

Indexed as

Endocrine disruptionMetabolism disruptorMethyltert-butyl etherMode of actionMTBEWeight of evidence

Identifiers

PMID42057916
PMCPMC13123375

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.